Oncolytics Biotech Inc近日公布了其Goblet研究中队列4的最新临床数据。该数据进一步证实了其核心候选药物Pelareorep与免疫检查点抑制剂Atezolizumab联合用药方案,在针对接受过三线治疗的肛门癌患者群体中,展现出令人鼓舞的治疗活性。
此次数据更新为这一难治性癌症的治疗前景提供了新的见解。
Oncolytics Biotech Inc近日公布了其Goblet研究中队列4的最新临床数据。该数据进一步证实了其核心候选药物Pelareorep与免疫检查点抑制剂Atezolizumab联合用药方案,在针对接受过三线治疗的肛门癌患者群体中,展现出令人鼓舞的治疗活性。
此次数据更新为这一难治性癌症的治疗前景提供了新的见解。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.